OVIOPEPTIDES
Research Use OnlyGet free bacteriostatic water added to your next order when you join the list.
RETATRUTIDE - Image 1

RETATRUTIDE

(50)
1
OVIO
PEPTIDES
Price
$80.00
99%+ Purity
3rd Party Tested
Fast Shipping
Discreet Package

Lab Results

Research brief

Retatrutide (LY-3437943) — Canada Research Brief

Last updated April 11, 2026

Retatrutide is an investigational triple-agonist peptide that simultaneously activates the GLP-1, GIP, and glucagon receptors, developed by Eli Lilly for obesity and type 2 diabetes.

Key facts

Canonical nameRetatrutide
Alternate namesLY-3437943, LY3437943
Drug classTriple-agonist peptide (GLP-1 / GIP / glucagon receptor)
CAS number2381089-83-2
Molecular formulaC221H342N46O68
Molecular weight4731.41 g/mol
Read full brief

Reconstitution Guide

Add bacteriostatic water to achieve your desired concentration:

1ml BAC water10.0mg/ml
2ml BAC water5.0mg/ml
2.5ml BAC water4.0mg/ml

Inject water slowly against vial wall. Swirl gently, do not shake.

About This Product

RETATRUTIDE Canada - The Next Generation of Metabolic Research Retatrutide represents a groundbreaking advancement in metabolic research as the first triple receptor agonist peptide. Unlike single or dual agonists, Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, creating a comprehensive approach to metabolic regulation that researchers worldwide are studying with intense interest. WHAT MAKES RETATRUTIDE UNIQUE Retatrutide's triple-action mechanism distinguishes it from all previous metabolic peptides. The GLP-1 activation regulates appetite signaling and glucose-dependent insulin secretion. GIP receptor binding enhances these effects while adding beneficial impacts on fat tissue metabolism. The glucagon component promotes hepatic fat oxidation and energy expendit...

Form

Lyophilized Powder

Quantity

10mg

Storage

-20°C

Share:

Customer Reviews (50)

Research brief

Retatrutide (LY-3437943) — Canada Research Brief

Mechanism

Retatrutide is a 39-amino-acid synthetic peptide that simultaneously activates three receptors involved in glucose and energy homeostasis:

  • GLP-1 receptor — enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite centrally.
  • GIP receptor — potentiates insulin secretion in the presence of hyperglycaemia and contributes to adipose-tissue handling of fatty acids.
  • Glucagon receptor — increases energy expenditure and hepatic thermogenesis, offsetting some of the fat-storage effects seen with incretin-only agonists.

Adding glucagon receptor activity to the familiar GLP-1 / GIP backbone is what distinguishes retatrutide from tirzepatide. In the phase-2 READY 1 trial (Jastreboff et al., NEJM 2023), retatrutide produced mean placebo- adjusted weight reductions of up to −22.1% at 48 weeks in the 12 mg cohort — the largest mean reduction reported for any peptide drug candidate at the time of publication.

Clinical trial status

As of publication, retatrutide is in phase-3 trials for obesity (TRIUMPH program) and type 2 diabetes, sponsored by Eli Lilly. None of these trials are complete. Retatrutide is not approved by Health Canada, the FDA, the EMA, or any other regulator. Its availability as a research peptide is based on its status as a synthesisable compound with a published structure, not on any approved clinical use.

How Canadian researchers source retatrutide

Canadian labs sourcing retatrutide should verify three things on any vendor: (1) per-batch HPLC purity ≥98%, (2) mass spectrometry confirming a molecular weight of 4,731.41 g/mol, and (3) domestic Canadian shipping to avoid CBSA holds on international incretin peptide shipments.

Comparisons

Regulatory framing in Canada

Retatrutide is not a Health Canada approved drug, not a prescription item, and not a natural health product. It is sold in Canada only as a research chemical under the non-clinical-use framing described in our peptides in Canada guide.

Frequently asked questions

What is retatrutide?
Retatrutide (LY-3437943) is an investigational synthetic peptide developed by Eli Lilly that acts as an agonist at three incretin and glucagon receptors simultaneously — GLP-1, GIP, and glucagon. It is in late-stage clinical trials for obesity and type 2 diabetes but is not yet approved by Health Canada, the FDA, or any other regulator.
How does retatrutide differ from tirzepatide and semaglutide?
Semaglutide is a single GLP-1 agonist. Tirzepatide is a dual GLP-1 / GIP agonist. Retatrutide adds a third receptor — glucagon — which in preclinical and phase-2 data produced larger mean weight reductions than either of the simpler agonists. Retatrutide remains investigational and has not been compared head-to-head in phase-3 trials.
Is retatrutide approved in Canada?
No. Retatrutide is not approved by Health Canada. It is an investigational compound in clinical trials and is sold in Canada strictly as a research chemical for non-clinical laboratory use only.
What is retatrutide's molecular weight?
Retatrutide has a molecular weight of 4,731.41 g/mol and a molecular formula of C221H342N46O68. Its CAS number is 2381089-83-2.

References

  1. [1]Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 2023. DOI: 10.1056/NEJMoa2301972
  2. [2]U.S. National Library of Medicine. Retatrutide — ClinicalTrials.gov registry, 2024
  3. [3]National Center for Biotechnology Information. PubChem CID 171390338 — Retatrutide, 2024

Related research

Frequently Asked Questions

What is RETATRUTIDE used for in research?

RETATRUTIDE is a triple receptor agonist primarily used for metabolic research. Activates GLP-1, GIP, and glucagon receptors simultaneously for comprehensive metabolic regulation. Researchers study RETATRUTIDE for its effects on fat loss, appetite suppression, glucose metabolism.

Can I buy RETATRUTIDE in Canada?

Yes, OVIOPEPTIDES ships RETATRUTIDE across all Canadian provinces including Ontario, British Columbia, Alberta, Quebec, Manitoba, Saskatchewan, and all territories. Our RETATRUTIDE is available for non-clinical laboratory research purposes only.

What purity is your RETATRUTIDE?

All RETATRUTIDE from OVIOPEPTIDES is verified at 99%+ purity through independent third-party HPLC testing. Every order includes a Certificate of Analysis confirming purity, molecular weight, and identity verification.

How should I store RETATRUTIDE?

Store lyophilized RETATRUTIDE powder at -20°C (freezer) in its original sealed vial. Once reconstituted with bacteriostatic water, refrigerate at 2-8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles.

How do I reconstitute RETATRUTIDE?

To reconstitute RETATRUTIDE, inject bacteriostatic water slowly against the vial wall. Swirl gently - never shake. Common reconstitution volumes are 1ml, 2ml, or 2.5ml depending on desired concentration. Allow the powder to dissolve completely before use.

Is RETATRUTIDE legal in Canada?

RETATRUTIDE is legal to purchase in Canada for non-clinical laboratory research purposes. It is not approved by Health Canada for therapeutic use and is not intended for human consumption. OVIOPEPTIDES sells RETATRUTIDE strictly for research applications.

How does RETATRUTIDE compare to semaglutide?

RETATRUTIDE and semaglutide are both used in metabolic research but have different mechanisms. RETATRUTIDE is a triple receptor agonist, while semaglutide may work through different pathways. Researchers often study these peptides together for comparative analysis.

What documentation comes with RETATRUTIDE?

Every RETATRUTIDE order from OVIOPEPTIDES includes a Certificate of Analysis (COA) documenting: HPLC purity results (99%+), mass spectrometry data, batch number, manufacturing date, and expiration date. This ensures full traceability for your research.